Patents Assigned to Sloan Kettering Institute
-
Patent number: 11913021Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.Type: GrantFiled: November 16, 2020Date of Patent: February 27, 2024Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer ResearchInventors: Shahin Rafii, Fan Zhang, Marco Seandel
-
Publication number: 20240050486Abstract: The present disclosure provides methods for generating cortical excitatory neurons, cortical excitatory neurons generated by such methods, and composition comprising such cells. The present disclosure also provides uses of the cortical excitatory neurons and composition comprising thereof for preventing and/or treating neurodegenerative disorders.Type: ApplicationFiled: July 7, 2023Publication date: February 15, 2024Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied DiseasesInventors: Lorenz Studer, Gabriele CICERI
-
Publication number: 20240050385Abstract: The present disclosure relates to the use of iron chelation to prevent and/or treat leptomeningeal metastasis. In certain embodiments, the present disclosure provides methods for the prevention and/or treatment of leptomeningeal metastasis that include the administration of an iron chelator to a subject. The present disclosure further provides kits for performing such methods.Type: ApplicationFiled: January 17, 2023Publication date: February 15, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Adrienne Boire, Yudan Chi
-
Publication number: 20230381315Abstract: The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising: an antigen-recognizing receptor (e.g., a chimeric antigen receptor, a TCR, or a TCR like fusion molecule); and a gene disruption of a CD70 locus. The gene disruption of the CD70 locus can improve the activity and/or efficiency of the cells.Type: ApplicationFiled: April 25, 2023Publication date: November 30, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Michel Sadelain, Jorge Mansilla-Soto, Sacha P. Haubner
-
Publication number: 20230372551Abstract: The present disclosure provides compounds, complexes, compositions, and methods for the detection of cancer. Specifically, the compounds, complexes, compositions of the present technology include pH (low) insertion peptides. Also disclosed herein are methods of using the complexes and compositions of the present technology in diagnostic imaging to detect cancer in a subject.Type: ApplicationFiled: September 21, 2021Publication date: November 23, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES, PHLIP, INC.Inventors: Jason S. LEWIS, Yana K. RESHETNYAK, Lukas M. CARTER, David BAUER
-
Publication number: 20230364276Abstract: Provided herein is a one-step method for chelating actinium-225 to a construct comprising a chelator linked to a biomolecule, such as, an antibody or monoclonal antibody, via a bifunctional ligand in, for example, a 3-arm configuration. Also provided are methods for increasing the radiochemical yield of an actinium-225-chelant-biomolecule complex and for producing a high specific activity actinium-225 complex. The chelation is performed at a physiological temperature, about 37° C. Also provided are high specific activity actinium-225 complexes, that is, actinium-225 chelated to the chelator-biomolecule construct and pharmaceutical compositions thereof. Further provided are methods of treating a neoplastic disease or disorder with the actinium-225 complexes.Type: ApplicationFiled: April 24, 2023Publication date: November 16, 2023Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Peter M. Smith-Jones, Michael R. McDevitt, William F. Maguire
-
Publication number: 20230346938Abstract: The presently disclosed subject matter provides chimeric antigen receptors (CARs) that specifically target CD19 and cells comprising such CD19-targeted CARs. The presently disclosed subject matter further provides uses of the CD19-targeted CARs for treatment, e.g., for treating blood cancer.Type: ApplicationFiled: October 24, 2022Publication date: November 2, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORAIL HOSPITAL FOR CANCER AND ALLIED DISEASES, MILLENNIUM PHARMACEUTICALS, INC.Inventors: Judith FEUCHT, Jorge MANSILLA-SOTO, Isabelle RIVIERE, Michel SADELAIN, Loic VINCENT, Gary SHAPIRO, Mei Rosa NG, Dan TAVARES, Xingyue HE
-
Patent number: 11760758Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.Type: GrantFiled: February 16, 2021Date of Patent: September 19, 2023Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Andrew C. Kruegel, Dalibor Sames, Srijita Bhowmik, Vaclav Havel, Juraj Galeta, Jonathan A. Javitch, Susruta Majumdar
-
Patent number: 11666550Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: GrantFiled: May 26, 2021Date of Patent: June 6, 2023Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Patent number: 11607465Abstract: This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.Type: GrantFiled: July 21, 2020Date of Patent: March 21, 2023Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Gabriela Chiosis, Naga Vara Kishore Pillarsetty, Jason S. Lewis, Steven M. Larson, Tony Taldone, Mary L. Alpaugh, Erica M. Gomes-DaGama
-
Publication number: 20230058774Abstract: The present disclosure provides novel dominant negative Fas polypeptides comprising a first modification in the cytoplasmic domain and a second modification in the N-terminal region of human Fas. The present disclosure also provides cells comprising such novel dominant negative Fas polypeptides and an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)). Also provided are uses of the cells for treatment, e.g., for treating tumors and pathogen infections.Type: ApplicationFiled: July 6, 2022Publication date: February 23, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Christopher A. Klebanoff, Fei Yi
-
Publication number: 20230051518Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to cells comprising a c-Kit mutant, e.g., a c-Kit mutant comprising an activating mutation. The cells can further comprise an antigen-recognizing receptor (e.g., a chimeric antigen receptors (CAR) or a T cell receptors (TCR)). The presently disclosed subject matter relates to the use of cells for treatment, e.g., treating cancers.Type: ApplicationFiled: June 3, 2022Publication date: February 16, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Prasad S. Adusumilli, Yuquan Xiong
-
Patent number: 11564988Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: GrantFiled: September 9, 2019Date of Patent: January 31, 2023Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Publication number: 20220363775Abstract: The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.Type: ApplicationFiled: April 25, 2022Publication date: November 17, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, MILLENNIUM PHARMACEUTICALS, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Michel Sadelain, Sascha P. Haubner, Jorge Mansilla-Soto, Xingyue He, Gary Shapiro
-
Patent number: 11447515Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: GrantFiled: June 16, 2017Date of Patent: September 20, 2022Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
-
Patent number: 11419955Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: GrantFiled: December 13, 2019Date of Patent: August 23, 2022Assignees: Sloan-Kettering Institute for Cancer Research, Cornell UniversityInventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
-
Publication number: 20220218748Abstract: The presently disclosed subject matter provides cells and compositions for improved immunotherapy and methods of using such cells and compositions. It relates to cells comprising a ligand-recognizing receptor (e.g., an antigen-recognizing receptor, e.g., a chimeric antigen receptor (CAR) or a T-cell Receptor (TCR)) and an IgG-degrading enzyme or a fragment thereof. The IgG-degrading enzyme rapidly cleaves IgG. The IgG-degrading enzyme serves as a biomolecular shield against the host humoral response. The cells have increased resistance to host humoral response (e.g., an antibody-driven host humoral response), which allows for prolonged persistence of the cells, leading to enhanced activity of the cells.Type: ApplicationFiled: February 1, 2022Publication date: July 14, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: David A. Scheinberg, Leila Peraro
-
Publication number: 20220213211Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD371 and cells comprising such CD371-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD371-targeted antigen-recognizing receptors for treatment.Type: ApplicationFiled: March 11, 2022Publication date: July 7, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
-
Publication number: 20220195064Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD371 and methods of using such antibodies or antigen-binding fragments thereof same.Type: ApplicationFiled: March 11, 2022Publication date: June 23, 2022Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
-
Publication number: 20220135564Abstract: The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and methods of using the compound to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorder, and opioid withdrawal symptoms.Type: ApplicationFiled: January 30, 2020Publication date: May 5, 2022Applicants: The Trustees of Columbia University in the City of New York, The Research Foundation for Mental Hygiene, Inc., Sloan-Kettering Institute for Cancer ResearchInventors: Andrew C. Kruegel, Dalibor Sames, Jonathan A. Javitch, Susruta Majumdar